Serum Institute of India CEO Adar Poonawalla said that clinical trials of Covid vaccine Covovax have begun in India and the company hopes to launch it by September this year.
In August 2020, US-based vaccine maker Novavax had announced a licence agreement with SII for the development and commercialisation of its Covid vaccine candidate in low- and middle-income countries and India. “It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%,” Poonawalla said in a tweet. Novavax continues to retain rights to develop and commercialise the drug for major upper-middle and high-income countries.
SII is already supplying the AstraZeneca/Oxford Covid vaccine, Covishield, in India and across the world.